Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
This is an open, multi-cohort, multi-center, exploratory and phase II clinical trial. To evaluate the efficacy and safety Anlotinib combined with chemotherapy as first-line and maintenance therapy for Gastrointestinal Tumors with Unresectable Liver Metastases.
Gastrointestinal Tumors
DRUG: Anlotinib + Oxaliplatin + Capecitabine|DRUG: Anlotinib + Cisplatin + Paclitaxel/ Docetaxel|DRUG: Anlotinib + Standard first-line chemotherapy
Objective response rate (ORR), Objective response rate is defined as the percentage of subjects whose best response was complete response (CR) or partial response (PR) according to the RECIST v1.1., up to 24 months
Progression-free survival (PFS), Progression-free survival is defined as the time from enrollment to the date of first document disease progression or death from any cause., up to 24 months|Disease Control Rate (DCR), Disease control rate is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the RECIST v1.1., up to 24 months|Duration of Response (DoR), Duration of Response is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the RECIST v1.1 or death due to any cause, whichever occurs first., up to 24 months|Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0)., Until 30 day safety follow-up visit|Overall Survival (OS), Overall Survival (OS) is defined as the time from enrollment to death from any cause., Up to 24 months|Radical Resection Rate of Liver Metastases, Radical Resection Rate of Liver Metastases is defined as the percentage of subjects whose liver metastases from unresectable to resectable., Up to 6 cycles
This is an open, multi-cohort, multi-center, exploratory and phase II clinical trial. To evaluate the efficacy and safety Anlotinib combined with chemotherapy as first-line and maintenance therapy for Gastrointestinal Tumors with Unresectable Liver Metastases.